
J Neuropsychiatry Clin Neurosci 17:221-226, May 2005
© 2005 American Psychiatric Press, Inc.
Tardive Dyskinesia Predicts Prolactin Response to Buspirone Challenge in People With Schizophrenia
Joo-Cheol Shim, M.D., Ph.D.,
Young-Hoon Kim, M.D., Ph.D.,
Deanna L. Kelly, Pharm.D., BCPP,
Jung-Goo Lee, M.D. and
Robert R. Conley, M.D.
Received August 5, 2003; revised November 26, 2003; accepted March 16, 2004. From the Department of Psychiatry and Institute of Neuroscience, Inje University, Busan, Korea; the Maryland Psychiatric Research Center, University of Maryland, Baltimore, Baltimore, Maryland; the Department of Psychiatry, Dongsuh Hospital, Masan, Korea. Address correspondence to Dr. Conley, Maryland Psychiatric Research Center, Maple and Locust Streets, P.O. Box 21247, Baltimore, MD 21228; rconley{at}umaryland.edu (E-mail).
Prolactin response to buspirone was evaluated in patients with schizophrenia, with and without tardive dyskinesia (TD). Prolactin response in patients with schizophrenia without TD was significantly decreased, compared to healthy comparison subjects (F=6.36, df=5, p<0.0001). Furthermore, prolactin levels after administration of buspirone were not significantly increased from baseline. In contrast, there was no prolactin response difference between patients with schizophrenia and TD and healthy subjects. This finding suggests that decreased dopamine (D2) receptor sensitivity may result in lower risk of developing TD and may lead to a fuller understanding of the variable expression of D2-receptor mediated side effects.
Key Words: Tardive Dyskinesia Prolactin Response Buspirone
Get information about faster international access.
a>
Privacy Policy
Copyright © 2005
American Neuropsychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|